methyl 2,3-dihydroxy pentanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 英文名称: methyl 2,3-dihydroxy pentanoate
• 英文别名: Methyl 2,3-dihydroxypentanoate；methyl 2,3-dihydroxypentanoate
• 化学式: C₆H₁₂O₄
• 分子量: 148.159
• InChiKey: PMBZZBIURKJQJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 2,3-dihydroxy pentanoate 在 吡啶 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 36.0h， 生成 trans-(+/-)-1-benzyl-3-ethyl-2-methoxycarbonylaziridine
  参考文献：
  名称：

  α-酮酯的乙烯基三氟甲磺酸酯与伯胺的反应：氮丙啶羧酸酯的有效合成

  摘要：

  α-酮酯的乙烯基三氟甲磺酸酯与伯胺平稳反应，以高收率提供氮丙啶羧酸酯。在所有情况下，几乎没有或没有观察到立体选择性。机理研究表明，氮丙啶羧酸盐是在动力学控制下严格形成的。缺乏立体选择性的原因可以通过非选择性或较差的立体选择性质子转移来解释。

  DOI：

  10.1016/s0040-4020(02)01031-1
• 作为产物：
  描述：

  反-2-戊酸甲酯 在 四氧化锇 、 N-甲基吲哚酮 作用下， 以 水 、 丙酮 为溶剂， 反应 2.0h， 以90%的产率得到methyl 2,3-dihydroxy pentanoate
  参考文献：
  名称：

  α-酮酯的乙烯基三氟甲磺酸酯与伯胺的反应：氮丙啶羧酸酯的有效合成

  摘要：

  α-酮酯的乙烯基三氟甲磺酸酯与伯胺平稳反应，以高收率提供氮丙啶羧酸酯。在所有情况下，几乎没有或没有观察到立体选择性。机理研究表明，氮丙啶羧酸盐是在动力学控制下严格形成的。缺乏立体选择性的原因可以通过非选择性或较差的立体选择性质子转移来解释。

  DOI：

  10.1016/s0040-4020(02)01031-1

文献信息

• Composition for pattern formation, and pattern-forming method
  申请人：JSR CORPORATION

  公开号：US11370872B2

  公开（公告）日：2022-06-28

  A composition for pattern formation includes a first polymer, a second polymer and a solvent. The first polymer includes: a first block including a first structural unit derived from a substituted or unsubstituted styrene; and a second block including a second structural unit other than the first structural unit. The second polymer includes: the first structural unit; and a group bonding to at least one end of a main chain thereof and including a polar group. The polar group is preferably a hydroxy group or a carboxyl group. A number average molecular weight of the second polymer is preferably no greater than 6,000. A mass ratio of the second polymer to the first polymer is preferably no less than 0.15 and no greater than 0.4. The solvent preferably comprises a compound comprising a hydroxyl group and an alkyl ester group.

  一种用于图案形成的组合物包括第一聚合物、第二聚合物和溶剂。第一种聚合物包括：第一嵌段，其中包括源自取代或未取代苯乙烯的第一结构单元；以及第二嵌段，其中包括与第一结构单元不同的第二结构单元。第二种聚合物包括：第一种结构单元；以及与主链至少一端结合并包括极性基团的基团。极性基团最好是羟基或羧基。第二种聚合物的平均分子量最好不大于 6000。第二种聚合物与第一种聚合物的质量比最好不小于 0.15 也不大于 0.4。溶剂最好由包含羟基和烷基酯基的化合物组成。
• COMPOSITION FOR PATTERN FORMATION, AND PATTERN-FORMING METHOD
  申请人：JSR Corporation

  公开号：US20190135967A1

  公开（公告）日：2019-05-09

  A composition for pattern formation includes a first polymer, a second polymer and a solvent. The first polymer includes: a first block including a first structural unit derived from a substituted or unsubstituted styrene; and a second block including a second structural unit other than the first structural unit. The second polymer includes: the first structural unit; and a group bonding to at least one end of a main chain thereof and including a polar group. The polar group is preferably a hydroxy group or a carboxyl group. A number average molecular weight of the second polymer is preferably no greater than 6,000. A mass ratio of the second polymer to the first polymer is preferably no less than 0.15 and no greater than 0.4. The solvent preferably comprises a compound comprising a hydroxyl group and an alkyl ester group.
• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：BARRY CLIFTON

  公开号：WO2011087995A2

  公开（公告）日：2011-07-21

  This invention provides compounds which are useful in the treatment of mycobacterial infections, pharmaceutical compositions containing the compounds, processes for their preparation, and uses of the compounds in various medicinal applications, such as the treatment or prevention of mycobacterial infections, such as those caused by Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium leprae, Mycobacterium africanum, Mycobacterium avium, Mycobacterium microti, or any mycobacterium that causes multi-drug resistant (MDR) TB or extensively resistant (XDR) TB, or any other mycobacterial species known to cause disease in humans; or the treatment or prevention of parasitic diseases, such as those caused by a parasite of the genus Trypanosoma, e.g. Trypanosoma cruzi or Trypanosoma brucei or a parasite of the genus Leishmania which causes visceral leishmaniasis or kala-azar, e.g., Leishmania donovani.